243 related articles for article (PubMed ID: 20143466)
1. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.
Biffi R; Fazio N; Luca F; Chiappa A; Andreoni B; Zampino MG; Roth A; Schuller JC; Fiori G; Orsi F; Bonomo G; Crosta C; Huber O
World J Gastroenterol; 2010 Feb; 16(7):868-74. PubMed ID: 20143466
[TBL] [Abstract][Full Text] [Related]
2. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
Brenner B; Shah MA; Karpeh MS; Gonen M; Brennan MF; Coit DG; Klimstra DS; Tang LH; Kelsen DP
Ann Oncol; 2006 Sep; 17(9):1404-11. PubMed ID: 16788003
[TBL] [Abstract][Full Text] [Related]
4. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
5. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.
Aoyama T; Nishikawa K; Fujitani K; Tanabe K; Ito S; Matsui T; Miki A; Nemoto H; Sakamaki K; Fukunaga T; Kimura Y; Hirabayashi N; Yoshikawa T
Ann Oncol; 2017 Aug; 28(8):1876-1881. PubMed ID: 28486692
[TBL] [Abstract][Full Text] [Related]
6. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
8. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
Ozdemir N; Abali H; Vural M; Yalcin S; Oksuzoglu B; Civelek B; Oguz D; Bostanci B; Yalcin B; Zengin N
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1139-47. PubMed ID: 25234436
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
11. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer.
Yu YJ; Sun WJ; Lu MD; Wang FH; Qi DS; Zhang Y; Li PH; Huang H; You T; Zheng ZQ
World J Gastroenterol; 2014 Dec; 20(48):18413-9. PubMed ID: 25561810
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Newman E; Marcus SG; Potmesil M; Sewak S; Yee H; Sorich J; Hayek M; Muggia F; Hochster H
J Gastrointest Surg; 2002; 6(2):212-23; discussion 223. PubMed ID: 11992807
[TBL] [Abstract][Full Text] [Related]
15. The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
Guo MG; Zheng Q; Cheng Z; Wang Y; Feng CN; Yang Z
Surg Oncol; 2010 Mar; 19(1):1-3. PubMed ID: 19006661
[TBL] [Abstract][Full Text] [Related]
16. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Roth AD; Fazio N; Stupp R; Falk S; Bernhard J; Saletti P; Köberle D; Borner MM; Rufibach K; Maibach R; Wernli M; Leslie M; Glynne-Jones R; Widmer L; Seymour M; de Braud F;
J Clin Oncol; 2007 Aug; 25(22):3217-23. PubMed ID: 17664469
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer.
Fushida S; Nashimoto A; Fukushima N; Kawachi Y; Fujimura T; Kuwabara S; Musha N;
Jpn J Clin Oncol; 2012 Feb; 42(2):131-3. PubMed ID: 22167664
[TBL] [Abstract][Full Text] [Related]
19. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
20. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
Ajani JA; Mansfield PF; Lynch PM; Pisters PW; Feig B; Dumas P; Evans DB; Raijman I; Hargraves K; Curley S; Ota DM
J Clin Oncol; 1999 Aug; 17(8):2403-11. PubMed ID: 10561303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
